Therefore, blocking the TBK1-IRF3-IL-33 signaling axis with statins represents a safe, effective, and readily accessible strategy to prevent chronic inflammation and its cancer sequela, which can impact many individuals at high risk of developing cancer-prone chronic inflammation. Here, IL33 is linked to cancer.